The upgrade of Passage Bio to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

PASG stock opened at $0.47 on Tuesday. Passage Bio has a 52-week low of $0.38 and a 52-week high of $1.79. The firm has a market cap of $29.04 million, a P/E ratio of -0.40 and a beta of 1.55. The ...

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and ...

PASSAGE BIO, INC. earnings at a glance (GAAP ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on March 4, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...

Passage Bio (NASDAQ:PASG – Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.21 ...

A replay of the presentation will be available for 30 days following the event. Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of ...

Passage Bio, Inc. (PASG) could be a solid choice for ... which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to ...